Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids

 
• By Joseph Haas
uterine-fibroids
AbbVie, Myovant and ObsEva are competing to bring a GnRH antagonist to market for UF

More from Strategy

More from Business